

Freedom of Information Request: Our Reference CTMUHB_290_23

You asked:

In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]:

- Berinert (Human C1-esterase inhibitor)
- Cinryze (Human C1-esterase inhibitor)
- Orladeyo (berotralstat)
- Takhzyro (Lanadelumab)
- Ruconest (Recombinant human C1-esterase inhibitor)
- Firazyr (Icatibant)
- Icatibant – any brand except Firazyr

Our response:

Please see provided below two tables populated with the data currently available. The period the data covers for Secondary Care refers to 1st April 23 to 30th June 23, and for Primary Care 1st February 2023 to 30th April 2023 the latest 3 months available. Unfortunately, we are unable to provide the information by number of patients due to the way the information is recorded in our systems.

Secondary Care

Medicine	Number of Issues
Berinert (Human C1-esterase inhibitor)	0
Cinryze (Human C1-esterase inhibitor)	0
Orladeyo (berotralstat)	0
Takhzyro (Lanadelumab)	0
Ruconest (Recombinant human C1-esterase inhibitor)	0
Firazyr (Icatibant)	0
Icatibant – any brand except Firazyr	5

Primary Care

Medicine	Number of Issues
----------	------------------

Berinert (Human C1-esterase inhibitor)	0
Cinryze (Human C1-esterase inhibitor)	0
Orladeyo (berotralstat)	0
Takhzyro (Lanadelumab)	0
Ruconest (Recombinant human C1-esterase inhibitor)	0
Firazyr (Icatibant)	0
Icatibant – any brand except Firazyr	0